Semaglutide (Ozempic) raises questions about mood and nonresponse
1. Reports of emotional flattening among some users of semaglutide (Ozempic) have brought new attention to how glucagon-like peptide-1 receptor ...
1. Reports of emotional flattening among some users of semaglutide (Ozempic) have brought new attention to how glucagon-like peptide-1 receptor ...
1. In this randomized controlled trial, tirzepatide produced substantially greater reductions in HbA1c, body weight, waist circumference, and BMI than ...
1. In this randomized controlled trial, switching from dulaglutide to tirzepatide was associated with greater improvements in patient-reported quality of ...
1. In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in adults with ...
1. In this randomized controlled trial, among adults with obesity, it was found that tirzepatide resulted in a significantly greater ...
Key Points: 1. Deal worth up to $1.3 billion brings AI-powered GPCR target discovery into Lilly’s obesity and cardiometabolic pipeline. ...
1. In this post-hoc analysis of the SURMOUNT-1 trial, there was a mostly linear relationship between percentage change in weight ...
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was found ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.